Phoenix Data Systems Captures Three New EDC Clients in July

King of Prussia, Pa. – Aug. 22, 2005 – Three new customers, including Morphotek Inc., Vitae Pharmaceuticals, Inc. and a medical device subsidiary of a top pharmaceutical conglomerate, signed agreements in July with Phoenix Data Systems to use the company's electronic data capture solutions.

Morphotek (www.morphotek.com) is a biotechnology company focused on the generation of proprietary therapeutics using "morphogenics" technology to develop optimized therapeutic antibodies for the treatment of cancer, inflammatory and infectious diseases. Morphotek is using PDS Express(TM) for an early phase study of MORAb-003, a humanized monoclonal antibody. The clinical trial is designed as an open label dose escalation safety study in patients with chemo-refractive ovarian cancer.

"The Phoenix Data Systems team has been exceptionally responsive," said Martin Phillips, senior vice president of clinical development. "This will be our first study using EDC and Phoenix Data Systems has helped us to make a quick transition to electronic processes. We expect to realize major efficiencies with real-time access to our study data."

Morphotek is also using Phoenix Data Systems' data management services in combination with PDS Express to support its trial. Phoenix Data Systems provides a full range of customized data management services, including forms design, trial-related reporting and management tools, enhanced EDC services and more, to support growing companies who outsource some or all of their data services.

Vitae will use PDS Express to collect data for a Phase I/IIa study being planned. Vitae expects to gain improved insights into their study data by using PDS Express. Vitae Pharmaceuticals is an emerging pharmaceutical company dedicated to discovering, developing and commercializing small molecule drugs that provide superior efficacy, tolerability and/or safety for significant unmet medical needs.

"Signing three new clients in a single month in this highly competitive marketplace is testament to the value our customers receive," said Dr. William Claypool, chief executive officer of Phoenix Data Systems. "PDS Express will give these clients significant control over collecting study data, better visibility toward study subject safety, and higher quality data. The diversity of the studies and these new clients show the flexibility of PDS Express to satisfy the requirements of a broad range of clients and study phases."

Phoenix Data Systems derives 100 percent of its revenue from electronic data capture implementations. The company's solutions can be adapted to fit the specific needs of a study, no matter which phase, in a flexible configuration that allows sponsors to control when and how they retrieve data. Predetermined pricing ensures sponsors won't experience cost overruns should changes occur during the study.

Founded in 1997, Phoenix Data Systems' solutions have been proven in more than 250 trials, including pivotal studies for eight new drug applications, without a single cost overrun. Nearly all of the company's existing clients renewed contracts in 2005 to conduct additional trials. More information is available at www.phoenixdatasystems.net